Evergreen Park, Illinois Clinical Trials

A listing of Evergreen Park, Illinois clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 767 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

University of Chicago /ID# 164115
 (6.5 away) Contact site
  • 254 views
  • 29 Apr, 2021
  • +134 other locations
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828 at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will …

lymphoid malignancy
FGFR1
myeloid neoplasm
The University of Chicago Medical Center
 (6.5 away) Contact site
  • 79 views
  • 14 Dec, 2020
  • +34 other locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

cancer
primary cancer
FGFR2
metastatic cancer
University of Chicago Medical Center
 (6.5 away) Contact site
  • 157 views
  • 14 Dec, 2020
  • +154 other locations
featured
ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Adult Subjects with Recurrent Clostridioides difficile Infection (RCDI)

ECOSPOR IV is a Phase 3, multicenter, Open Label study to evaluate the safety and tolerability of SER-109 in adult subjects with recurrent CDI.

clostridium difficile
The University of Chicago Medical Center
 (6.5 away) Contact site
  • 41 views
  • 21 Dec, 2020
  • +76 other locations
featured
ECOSPOR III: A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults

ECOSPOR III is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in adult subjects 18 years of age or older with recurrent CDI, defined as: a history of ≥ 3 CDI episodes within 9 months, inclusive of the current …

antibiotic therapy
antibiotics
clostridium difficile
vancomycin
fidaxomicin
The University of Chicago Medical Center
 (6.5 away) Contact site
  • 1092 views
  • 21 Dec, 2020
  • +71 other locations
featured
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Carcinoma

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

solid tumors
cancer
University of Chicago Medical Center
 (6.5 away) Contact site
  • 25 views
  • 14 Dec, 2020
  • +8 other locations
featured
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).  

carcinoma
metastatic merkel cell carcinoma
merkel cell carcinoma
cancer
measurable disease
RUSH UNIVERSITY
 (5.0 away) Contact site
  • 101 views
  • 14 Dec, 2020
  • +6 other locations
featured
GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

graft-versus-host disease
University of Chicago
 (6.5 away) Contact site
  • 1462 views
  • 08 Dec, 2020
  • +10 other locations
featured
Phase 1 study of BAY1905254 - An early clinical research study to evaluate a new drug called Bapotulimab (BAY1905254) in the expansion cohort in combination with Pembolizumab in Head and Neck cancer that has returned or is discovered to be metastatic and is expressing PDL1.

This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab.  The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it affects the body and to try to find the best …

carcinoma
squamous cell carcinoma
pembrolizumab
metastatic head and neck cancer
metastatic head and neck squamous cell carcinoma
University of Chicago Hospitals
 (6.7 away) Contact site
  • 0 views
  • 02 Jul, 2021
  • +7 other locations
featured
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

University of Chicago Medical Center
 (6.5 away) Contact site
  • 326 views
  • 08 Nov, 2020
  • +26 other locations